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Abstract
Background: Pharmaceutical firms heavily promote their products and may have changed marketing strategies in response
to reductions in new product approvals, restrictions on some forms of promotion, and the expanding role of biologic
therapies.
Methods: We used descriptive analyses of annual cross-sectional data from 2001 through 2010 to examine direct-to-
consumer advertising (DTCA) (Kantar Media) and provider-targeted promotion (IMS Health and SDI), including: (1) inflation-
adjusted total promotion spending ($ and percent of sales); (2) distribution by channel (consumer v. provider); and (3)
provider specialty both for the industry as a whole and for top-selling biologic and small molecule therapies.
Results: Total promotion peaked in 2004 at US$36.1 billion (13.4% of sales). By 2010 it had declined to $27.7B (9.0% of sales).
Between 2006 and 2010, similar declines were seen for promotion to providers and DTCA (both by 25%). DTCA’s share of
total promotion increased from 12% in 2002 to 18% in 2006, but then declined to 16% and remains highly concentrated.
Number of products promoted to providers peaked in 2004 at over 3000, and then declined 20% by 2010. In contrast to
top-selling small molecule therapies having an average of $370 million (8.8% of sales) spent on promotion, top biologics
were promoted less, with only $33 million (1.4% of sales) spent per product. Little change occurred in the composition of
promotion between primary care physicians and specialists from 2001–2010.
Conclusions: These findings suggest that pharmaceutical companies have reduced promotion following changes in the
pharmaceutical pipeline and patent expiry for several blockbuster drugs. Promotional strategies for biologic drugs differ
substantially from small molecule therapies.
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Introduction
In the United States, pharmaceuticals are heavily promoted to
providers and patients. The pharmaceutical industry spent nearly
$30 billion dollars in 2005 on marketing and promotion, of which
84% went toward physician detailing and free samples, with less
devoted to professional advertising and direct-to-consumer adver-
tising (DTCA) [1,2]. Spending varied considerably by product,
although both detailing and DTCA tended to favor drugs with
broader clinical indications for use [3]. Pharmaceutical promotion
can influence demand for prescription drugs [4], increase
physician visits for conditions treated by heavily advertised drugs
[5] and affect physician prescribing [6].
Little is known about how pharmaceutical companies have
altered promotional spending in response to major health care
changes. First, during the past decade there has been a slowdown
in new drug introductions. During the second half of the 1990s,
the FDA approved a large number of small molecule therapies for
common conditions, including many drugs that were the first of
their kind. These ‘‘blockbuster’’ drugs were heavily marketed,
resulting in a 162% increase in total promotional spending
between 1996 and 2005 [1]. In recent years, however, blockbuster
drugs have faced increasing competition from generics, as well as
branded rivals, with the generic share of total prescriptions
increasing markedly from 63% in 2006 to nearly 80% in 2010 [7].
Fewer new drugs have been approved annually in recent years [8],





and a greater proportion of those introduced have been for orphan
conditions [9]. Second, drugs manufactured using biologic pro-
cesses, or ‘‘biologics’’, represent an increasing proportion of newly
approved products and drugs sales [10,11]. Biologics comprised
over 40% of products in late stage research and development in
2009, suggesting that they may account for an increasing
proportion of new products launched in the near future [10].
Since these products are often used by a smaller number of
patients, administered parenterally by providers, and sold at much
higher prices, the promotional strategies may differ substantially
compared to small molecule therapies. Finally, in response to
mounting empirical evidence as well as legal challenges, media
scrutiny [12], and the recommendations of professional societies
[13], numerous medical centers have limited pharmaceutical sales
representatives access to physicians [14–16]. Furthermore, certain
states now require disclosure of gifts from pharmaceutical
companies to providers [17]. While there is some evidence of
decreases in industry interaction with office-based physicians
[18,19], it is unclear how industry practices have changed in
response to these provisions.
We examined trends in promotion to consumers and providers
over the last decade. We hypothesized decreases in absolute
spending on promotion to providers and DTCA, with an
increasing share of detailing devoted to specialists given the
expanding role of biologics. In addition to trends for the
pharmaceutical industry overall, we compared the promotional
strategies of top-selling small molecule and biologic therapies.
Finally, to determine whether trends in promotion were correlated
with changes in the pharmaceutical pipeline, we examined the
number of products and spending per product promoted.
Methods
Data
We used the IMS Health Integrated Promotional ServicesTM to
obtain data on detailing, free samples dispensed to providers, and
journal advertisements. We obtained data from SDI on spending
for electronic promotion (e.g., Internet) targeting providers and for
meetings and conferences. IMS Health detailing estimates are
derived from a nationally representative audit of office- and
hospital-based providers as well as pharmacy directors. Office-
based detailing includes spending on service visits associated with
sample distribution. Estimates of units of free samples dispensed to
physicians are derived from an audit of office-based physician
practices, while their retail value is calculated based on suggested
retail prices. Journal advertising data is collected through a census
of all medical journals. Using directory information from the
American Medical Association, IMS also reports detailing
expenditures by physician specialty. SDI spending is based on
Table 1. Pharmaceutical promotion to consumers and providers 2001–2010.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Direct-to-consumer advertising (millions of 2010 dollars)
Television 2,184 2,061 2,367 3,213 3,150 3,270 3,194 2,951 2,919 2,375
Print 1,242 1,242 1,606 1,651 1,823 2,291 2,132 1,617 1,587 1,747
Internet 27 42 72 214 181 230 105 141 312 202
Radio 46 51 73 67 68 87 48 24 43 44
Outdoor 2 6 6 6 8 13 4 3 6 3
Total 3,500 3,402 4,124 5,151 5,231 5,891 5,483 4,738 4,868 4,371
As percentage of sales 1.7 1.4 1.6 1.9 1.9 2.0 1.9 1.6 1.6 1.4
Promotion to providers (millions of 2010 dollars)
Office-based promotion 5,897 6,450 7,442 7,621 6,892 6,780 6,147 6,043 5,906 5,306
Hospital-based promotion 864 1,071 1,005 1,059 881 718 620 490 491 479
Journal advertising 523 578 582 628 531 570 494 392 320 326
Free samples (retail value) 12,884 14,455 16,057 18,056 16,318 14,970 15,614 14,193 14,416 13,850
Epromotion (SDI) – – 251 255 314 356 415 497 532 525
Conferences and meetings (SDI) 2,605 2,644 2,890 3,295 3,027 2,851 2,910 2,993 2,952 2,840
Total 22,773 25,197 28,229 30,915 27,963 26,242 26,201 24,609 24,616 23,326
As percentage of sales 10.8 10.7 10.9 11.4 10.1 9.0 8.9 8.5 8.1 7.6
All DTCA and promotion to providers ($2010 millions) 26,274 28,599 32,352 36,065 33,194 32,133 31,685 29,347 29,484 27,697
All sales ($2010 billions) 212 236 260 270 276 292 296 290 305 307
As percentage of sales 12.4 12.1 12.5 13.4 12.0 11.0 10.7 10.1 9.7 9.0
Number of new molecular entities launched 31 28 30 21 20 27 21 19 26 21
Number of products marketed and promoted 2,920 3,087 3,056 3,105 3,094 2,680 2,730 2,660 2,576 2,474
Average promotion per product ($millions) 9.0 9.3 10.6 11.6 10.7 12.0 11.6 11.0 11.4 11.2
All financial data were adjusted to 2010 dollars, utilizing the Consumer Price Index – All Urban.
Sources: Direct-to-consumer advertising data provided by Kantar Media; promotion to professionals data derived from the IMS Health Integrated Promotional
ServicesTM, 2002–2010 with the exception of data regarding epromotion and conferences and meetings which was derived from the SDI Physician Meeting and Event
Audit and SDI ePromotion Audit; provider promotion for 2001 derived from reference #1; sales data derived from IMS Health Use of Medicines 2010 Report; newly
launched molecular entities derived from reference #10; number of products marketed and promoted derived from IMS Health Integrated Promotional ServicesTM and
includes products with any spending targeting providers.
doi:10.1371/journal.pone.0055504.t001
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a monthly audit of approximately 4,000 office-based providers
representing 19 specialties. Data are collected and projected by
region and specialty to represent a universe of approximately
380,000 practicing providers. Finally, Kantar Media provided
industry-wide and product-specific DTCA expenditures account-
ing for television, magazine, radio, outdoor, newspaper, and
Internet promotion. These estimates are drawn from a sample of
national media such as network TV and national newspapers as
well as local media sampled at the Designated Media Area level.
We used IMS Health sales figures [7], supplemented for certain
therapies with data from the IMS Health National Sales
PerspectivesTM, in order to calculate promotion and marketing
as a percentage of total sales. Estimates of the annual sales were
calculated based on unit sales from both retail and non-retail
channels and ex-manufacturer invoices (amount paid to whole-
salers or manufacturers net of prompt payment discounts). We
obtained data on the number of products on the market and, of
these, the number promoted each year using IMS Health National
Sales PerspectivesTM and Integrated Promotional ServicesTM. We
used a data set of drug launches [10], supplemented for 2009 and
2010 with the number of new molecular entities approved by the
Food and Drug Administration [20], to determine the number of
new molecular entities per year.
Biologic therapies were defined as those manufactured using
biologic processes [10], while the remainder of products were
categorized as small molecules.
Analyses
We used descriptive statistics to characterize six aspects of
promotion to providers: the retail value of free samples, office-
based detailing, hospital-based detailing, journal advertising,
epromotion and conferences and meetings. We quantified the
absolute and relative magnitude of annual total promotional
efforts towards providers. We also assessed the concentration of
promotion for top-selling small molecules and biologic therapies.
We obtained a list of the top-selling U.S. and European
biologics in 2010 [21]. We then identified additional biologics with
high sales expenditures [22] and used the IMS Health National
Sales PerspectivesTM to rank these therapies. Sales and pro-
motional expenditures were aggregated across all formulations of
a brand, and for the few molecules available both as mono-
therapies and fixed-dose combinations, we excluded sales and
Table 2. U.S. sales revenue and promotional spending for leading selling prescription medicines according to dollar sales in 2010.





DTCA Office Hospital Samples Journals All Provider Total
1 Lipitor Small molecule 7.2 272.0 97.3 7.6 359.7 4.3 468.8 740.8 10.3%
2 Nexium Small molecule 6.4 16.7 32.5 2.3 208.5 0.7 244.0 260.7 4.1%
3 Plavix Small molecule 6.1 127.3 60.1 9.1 93.3 0.2 162.7 290.0 4.8%
4 Seroquel Small molecule 5.2 80.6 51.2 11.8 91.0 0.0 153.9 234.5 4.5%
5 Advair Diskus Small molecule 4.7 200.5 47.5 1.8 343.4 0.0 392.7 593.2 12.6%
6 Abilify Small molecule 4.6 155.7 49.7 6.1 412.7 0.0 468.5 624.2 13.6%
7 Singulair Small molecule 4.1 70.3 69.5 3.6 309.5 0.04 382.6 452.9 11.0%
8 Crestor Small molecule 3.8 95.3 101.5 7.0 389.7 1.0 499.2 594.5 15.6%
9 Actos Small molecule 3.5 40.7 48.9 1.5 202.2 0.0 252.6 293.3 8.4%
10 Epogen Biologic 3.3 0 0.4 0.1 0.0 0.0 0.4 0.4 0.01%
11 Remicade Biologic 3.3 0 4.7 0.7 0.3 0.6 6.3 6.3 0.2%
12 Enbrel Biologic 3.3 71.5 9.9 0.9 8.1 1.2 20.1 91.6 2.8%
13 Zyprexa Small molecule 3.3 1.2 16.0 5.8 174.1 0.0 195.9 197.1 6.0%
14 Cymbalta Small molecule 3.2 206.0 93.6 7.2 309.6 4.0 414.4 620.4 19.4%
15 Avastin Biologic 3.1 0.0007 2.8 1.6 0.0 2.2 6.6 6.6 0.2%
16 Oxycontin Small molecule 3.1 0.1 9.9 0.9 0.0 2.6 13.4 13.5 0.4%
17 Lantus Biologic 3.0 46.5 37.2 4.7 58.3 8.3 108.5 154.9 5.1%
18 Neulasta Biologic 3.0 0.3 1.4 0.2 0.0 0.7 2.3 2.6 0.1%
19 Humira Biologic 2.9 34.1 12.9 3.8 25.4 0.1 42.2 76.3 2.6%
20 Lexapro Small molecule 2.8 2.1 108.2 6.7 270.9 13.1 398.8 400.9 14.3%
21 Rituxan Biologic 2.8 0.05 4.3 0.2 0.0 2.3 6.8 6.9 0.2%
22 Aricept Small molecule 2.5 34.3 25.5 2.6 154.1 2.2 184.5 218.8 8.8%
23 Lovenox Small molecule 2.3 0.1 7.3 8.5 3.2 0.0 19.0 19.1 0.8%
24 Atripla Small molecule 2.2 0.8 2.1 1.0 0.2 0.4 3.7 4.5 0.2%
25 Copaxone Biologic 2.2 0 4.0 0.7 2.3 0.2 7.2 7.2 0.3%
TOTAL – – 91 1,456 20% 2% 77% 1% 4,455 5,911 6.4%
Sources: Direct-to-consumer advertising data provided by Kantar Media; promotion to professionals data derived from the IMS Health Integrated Promotional
ServicesTM, 2010TM and excludes epromotion and expenditures for conferences and meetings depicted in Table 1; sales data derived from IMS Health Use of Medicines
2010.
doi:10.1371/journal.pone.0055504.t002
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promotional spending associated with combination therapies.
Except where otherwise noted, data on sales and promotional
spending were adjusted to 2010 dollars using the Consumer Price
Index – All Urban [23].
Results
Trends in Overall and Provider Promotion
Table 1 characterizes aggregate trends in marketing and
promotion. Total inflation-adjusted promotional spending peaked
in 2004 both in terms of absolute spending ($36.1 billion) and
spending relative to sales (13.4%). Afterward, spending declined
each year to $27.7B (9.0% of sales) by 2010. Nearly all forms of
promotion saw declines beginning in 2005. The retail value of free
samples declined 23%, or 11% when not adjusted for inflation,
from $18.1 B in 2004 to $13.9B in 2010. The expenditure shares
across the three major promotional categories were remarkably
stable. Despite a more than two-fold relative increase in electronic
promotion, this category accounted for less than 2% of provider
promotion in 2010.
Trends in Direct-to-consumer Advertising (DTCA)
DTCA peaked at $5.9B in 2006 followed by a 25% decline to
$4.4B by 2010. As a percentage of total promotional spending,
DTCA increased from 12% in 2002 to 18% in 2006, but declined
modestly to 16% by 2010. During this period, television accounted
for a decreasing proportion of all DTCA, declining from 62% in
2001 to 54% by 2010. Print DTCA increased 84% 2001–2006,
but then declined 24% by 2010. In 2010, internet promotion
accounted for less than 5% of overall consumer promotion.
Drug Launches and Overall Number of Products
Promoted
The number of new molecular entities launched ranged from 19
to 31 across the study period, with the greatest numbers of new
molecular entities introduced between 2001 and 2003 (Table 1).
Declines in the number of products promoted paralleled declines
in promotional spending. The average promotional spending per
product actually increased from $9.0M (2001) to $12.0M (2006),
then declined modestly to $11.2M (2010).
Table 3. Therapies most heavily promoted through direct-to-consumer advertising, 2010.
Ranking Trade name Type of drug
Spending in direct-to-consumer
advertising (millions)
1 Lipitor Statin 272
2 Cialis Phosphodiesterase type 5 inhibitor 216
3 Cymbalta Serotonin-norepinephrine reuptake inhibitor 206
4 Advair Inhaled corticosteroid and long-acting beta-agonist 200
5 Abilify Atypical antipsychotic 156
6 Symbicort Inhaled corticosteroid and long-acting beta-agonist 152
7 Pristiq Serotonin-norepinephrine reuptake inhibitor 127
8 Plavix Oral thienopyridine antiplatlet 127
9 Lyrica Anticonvulsant 112
10 Chantix Nicotinic receptor partial agonist 110
11 Toviaz Muscarinic antagonist 109
12 Viagra PDE5 inhibitor 100
13 Crestor Statin 95
14 Boniva Oral bisphosphonate 85
15 Lovaza Omega-3 fatty acid 81
16 Seroquel Atypical antipsychotic 81
17 Enbrel* Tumor necrosis factor inhibitor 72
18 Simponi* Tumor necrosis factor inhibitor 71
19 Spiriva Handihaler Anticholinergic bronchodilator 71
20 Singulair Leukotriene receptor antagonists 70
21 Januvia Dipeptidyle peptidase-4 (DPP-4) inhibitor 65
22 Restasis Cyclosporin topical emulsion 58
23 Vyvanse Psychostimulant 58
24 Trilipix Fibrate 56
25 Lunesta Non-benzodiazepine hypnotic 54
All 25 combined 2,805
Total percentage of industry DTCA spending 64
Source: Data provided by Kantar Media.
*Biologic therapy.
doi:10.1371/journal.pone.0055504.t003
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(thousands) Office Hospital Samples Journals
1 Epogen 3,325 0 447 447 0.01% 394 53 0 0
2 Remicade 3,303 0 6,270 6,270 0.2% 4,682 679 277 632
3 Enbrel 3,291 71,507 20,129 91,636 2.8% 9,864 931 8,143 1,192
4 Avastin 3,091 1 6,643 6,644 0.2% 2,837 1,570 0 2,237
5 Lantus 3,045 46,461 108,474 154,935 5.1% 37,178 4,696 58,284 8,316
6 Neulasta 3,011 252 2,291 2,543 0.1% 1,379 217 0 695
7 Humira 2,929 34,108 42,206 76,314 2.6% 12,894 3,778 25,390 144
8 Rituxan 2,762 45 6,780 6,825 0.2% 4,314 202 0 2,264
9 Copaxone 2,253 0 7,177 7,177 0.3% 3,983 723 2,256 216
10 NovoLog 2,097 4,496 53,130 57,626 2.7% 11,261 890 39,566 1,413
11 Humalog 1,608 13,665 57,805 71,470 4.4% 13,075 1,037 35,671 8,022
12 Herceptin 1,537 0 2,563 2,563 0.2% 1,544 264 0 754
13 Procrit/Eprex 1,466 13 2,277 2,290 0.2% 1,295 867 0 115
14 Lucentis 1,435 2,053 666 2,719 0.2% 274 53 0 339
15 Avonex 1,424 334 4,231 4,565 0.3% 2,965 487 258 521
16 Aranesp 1,305 0 3,470 3,470 0.3% 1,971 1,499 0 0
17 Neupogem 961 0 83 83 0.01% 74 9 0 0
18 Rebif 941 92 4,439 4,531 0.5% 3,952 41 0 446
19 Prevnar-7 829 16,277 6,851 23,128 2.8% 4,611 395 0 1,845
20 Betaseron 826 4 3,148 3,152 0.4% 2,857 20 0 271
21 Synagis 735 0 2,910 2,910 0.4% 2,181 728 0 0
22 Erbitux 709 0 3,640 3,640 0.5% 2,318 191 0 1,131
23 Levemir 673 144 82,889 83,033 12.3% 27,125 2,782 48,242 4,740
24 Byetta 571 42 113,461 113,503 19.9% 23,121 1,598 85,194 3,549
25 Pegasys 512 0 3,447 3,447 0.7% 3,016 431 0 0
TOTAL – 44,639 189,494 545,427 734,921 1.6% 33% 4% 56% 7%
Sources: Direct-to-consumer advertising data provided by Kantar Media; promotion to professionals data derived from the IMS Health Integrated Promotional
ServicesTM, 2010 and excludes epromotion and expenditures for conferences and meetings depicted in Table 1; sales data derived from IMS National Sales
PerspectivesTM.
doi:10.1371/journal.pone.0055504.t004
Table 5. Detailing spending and number contacts with primary care providers and specialists 2001–2010.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Spending on Office-Based Detailing
Primary Care, % – 62.0 – 62.3 61.9 61.0 60.9 60.5 60.6 60.3
Specialty, % – 38.0 – 37.7 38.1 39.0 39.1 39.5 39.4 39.7
Total (millions $2010) 5,897 6,450 7,442 7,621 6,892 6,780 6,147 6,043 5,906 5,306
Office-based Contacts
Primary Care, % 69.3 68.6 – 68.5 67.7 63.2 63.1 62.4 62.8 62.6
Specialty, % 30.7 31.4 – 31.5 32.3 36.7 36.9 37.5 37.2 37.3
Total (millions) 50.8 53.6 67.7 69.0 60.1 58.8 54.0 51.9 48.9 44.6
All data were adjusted to 2010 dollars, utilizing the Consumer Price Index. Primary care providers include those trained in family practice, general practice, internal
medicine, osteopathic medicine or pediatrics. Specialty providers were defined as all other provider types, including those trained in subspecialties of internal medicine
such as cardiology or gastroenterology.
‘‘–’’ indicates years when data was not available.
Source: IMS Health Integrated Promotional ServicesTM, 2001–2010.
doi:10.1371/journal.pone.0055504.t005
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Promotion of Top-selling Agents
Among the 25 top-selling products of 2010 listed in Table 2, 16
were small molecule therapies and the remaining nine were
biologics.
Levels and intensities of provider and consumer-directed
promotion were generally lower for biologics than small molecule
therapies. The top 15 small molecule therapies had an average
total promotional spending of $370 million in 2010 (8.8% of sales)
compared to only $33 million for the top 15 biologics (1.4% of
sales).
Products Most Heavily Promoted to Consumers
Table 3 displays the 25 drugs most heavily promoted to
consumers via DTCA. The drug most heavily promoted to
consumers in 2010 was Lipitor with $272M devoted to DTCA
alone followed by Cialis ($216M) and Cymbalta ($206M). DTCA
was concentrated in a small number of products. Only two of the
top 25 consumer-promoted products, etanercept (Enbrel) and
golimumab (Simponi), were biologic therapies, whereas biologics
accounted for 9 of the 25 top-selling products.
Promotion of Biologics
Table 4 reports top US-selling biologics along with product-
specific expenditures and promotional spending toward consumers
and providers. In 2010, epoetin alfa (Epogen), infliximab
(Remicade) and etanercept (Enbrel) led in biologic sales, each
with $3.3B. Among top-selling biologic therapies, 2010 promotion
was greatest for exenatide (Byetta) with 20% of its $571M in US
sales dedicated to promotion, followed by insulin detemir
(Levemir) with 12% and insulin glargine (Lantus) with 5% of its
$3.0B in U.S. sales dedicated to promotion. Promotion for 17 of
the other top-selling 25 biologics was less than 1% of sales.
Spending on promotion to providers varied widely across the
biologics examined, ranging from only $83,000 (filgrastim
[Neupogen]) to more than $100 million (insulin glargine [Lantus]
and exenatide [Byetta]). For the majority of therapies, office-based
detailing accounted for the largest expenditures; however, among
the minority of biologics that had any spending on free samples
(e.g., Byetta, Lantus, Levemir), this was generally the dominant
form of promotion. DTCA for biologics was limited to approx-
imately two-thirds of the 25 therapies examined.
Promotion to Primary Care Physicians and Specialists
Table 5 summarizes trends in detailing and contacts directed at
primary care providers and specialists (excluding free samples).
The proportion of office-based detailing directed at primary care
providers declined modestly from 69% of contacts in 2002 to 63%
in 2010. However, smaller decreases were evident in the share of
office-based detailing spending targeting primary care physicians.
Discussion
After steady increases in pharmaceutical marketing and pro-
motion to consumers and providers during the first half of the last
decade, since 2004 pharmaceutical firms have decreased both the
absolute value of spending as well as the share of sales devoted to
promotion. These declines in promotional spending do not seem
to primarily reflect waning consumer purchasing power, since
promotion has been declining in the context of rising sales [7].
Spending on meetings and electronic promotion has increased, yet
these channels still account for only a small fraction of provider
promotion. Despite its growth in the first half of the decade,
DTCA also represents a minority of promotion and is driven by
television advertising. Top-selling biologic therapies had far lower
promotional spending per product than did the top small molecule
therapies, with substantially less spent on free samples.
Declines in promotion as a percentage of sales since 2005 may
result in part from the ‘‘graying’’ of the market [1]. Whereas sales
for new drugs accounted for 34% of total sales in 1999 they
comprised only 19% of total sales in 2007 [8]. Reductions in new
molecular entity approvals are apparent when considering the
1990s. On average, 22 new molecular entities were introduced
annually in the 1980s, 31 in the 1990s, and 24 in the 2000s [24].
Declining promotion may also reflect the increasing biologics
share of the market [10]. Biologics often have unique routes of
delivery and storage and can be very costly compared to small
molecules, with costs for one cancer drug, Avastin, exceeding
$100,000 per year [25]. Given that use of new biologics is
concentrated among a smaller number of patients with relatively
rare conditions treated primarily by specialists, we would expect
promotion to providers and consumers to also be highly targeted.
Despite anecdotal reports [26,27] and calls from stakeholders
[27–29], we did not find evidence of substantial changes in the
proportion of provider-targeted promotion accounted for by
office-based detailing. In addition, we saw no substantial shifts in
the proportion of expenditures targeting primary care providers.
DTCA remains highly concentrated among a small number of
products and continues to account for a minority of promotional
spending [30]. Declines in DTCA may accelerate as biologics
make up a greater share of new therapies. Although relative
increases in DTCA through media such as the Internet and social
networking have occurred, these expenditures remain a small
fraction of overall consumer-targeted promotion.
Our study has several limitations. First, our analyses were not
designed to examine promotional content nor the causal effect of
promotional expenditures [31–33]. Second, some biologics have
unique distribution channels and thus our data capture may be
incomplete. The difficulty in measuring the extended units for
infused and injected therapies also prohibits us from estimating the
ratio of promotion to units of utilization. Third, while there are
a variety of methods of estimating promotion costs [34], we have
used a conventional commercial definition and have considered
only expenditures that are clearly directed at marketing rather
than attempting to approximate unmonitored promotion and the
R&D proportion that is promotional. Our estimates are similar to
those of Donohue et al [1] although here we include estimates of
expenditures for conferences and meetings as well as Epromotion
to providers. As with prior investigations [1], our estimations of
promotion devoted to free samples are based on their approximate
retail value and thus may overstate manufacturers’ costs. Finally,
to the extent medical care prices have increased more rapidly than
non-medical care prices, our use of the Consumer Price Index –
All Urban may underestimate the magnitude of the reduction in
inflation-adjusted drug spending since 2006.
Manufacturers of branded pharmaceuticals continue to expend
considerable sums on promotion to consumers and providers.
However, in the context of marketplace changes, firms are
decreasing spending but changing little about how expenditures
are allocated across types of promotion. An increasing role for
biologics to the market may cause more substantial shifts in future
promotional patterns.
Acknowledgments
The statements, findings, conclusions, views, and opinions contained and
expressed in this article are based in part on data obtained under license
from the following IMS Health Incorporated information service(s):
Integrated Promotional ServicesTM, 2001–2010 and IMS Health In-
corporated and National Sales PerspectivesTM, 2001–2010. All Rights
Promotion of Prescription Drugs
PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e55504
Reserved. The statements, findings, conclusions, views, and opinions
contained and expressed herein are those of the authors, and are not
necessarily those of IMS Health Incorporated or any of its affiliated or
subsidiary entities, or of the institutions with whom the authors are
affiliated.
Author Contributions
Supervision: GCA. Conceived and designed the experiments: RK JD EB
GCA. Performed the experiments: RK GCA. Analyzed the data: RK JD
EB GCA. Contributed reagents/materials/analysis tools: RK JD EB GCA.
Wrote the paper: RK.
References
1. Donohue JM, Cevasco M, Rosenthal MB (2007) A decade of direct-to-consumer
advertising of prescription drugs. N Engl J Med 357: 673–681.
2. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM (2002)
Promotion of prescription drugs to consumers. N Engl J Med 346: 498–505.
3. Campbell S (2009) Promotional Spending for Prescription Drugs. Congressional
Budget Office Economic and Budget Issue Brief. Available: http://www.cbo.
gov/ftpdocs/105xx/doc10522/12-02-DrugPromo_Brief.pdf. Accessed 2012
Sep 5.
4. Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank RG (2003)
Demand effects of recent changes in prescription drug promotion. Frontiers
Health Policy Res 6: 1–26.
5. Iizuka T, Jin GZ (2005) The effect of prescription drug advertising on drug visits.
J Econ Manag Strategy 14: 701–727.
6. Donohue JM, Berndt ER (2004) Effects of Direct-to-Consumer Advertising on
Medication Choice: The Case of Antidepressants. Journal of Public Policy and
Marketing. 23: 115–127.
7. IMS Institute for Healthcare Informatics (2011) The Use of Medicines in the
United States: Review of 2010. Available: www.theimsinsitute.org. Accessed
2012 Apr 27.
8. Aitken ML, Berndt ER, Cutler DM (2009) Prescription Drug Spending Trends
in the US: Looking Beyond the Turning Point. Health Aff (Millwood) 28: 151–
160.
9. Generic Pharmaceutical Association (GPhA) (2012) Savings: $1 Trillion Over 10
Years – Generic Drug Savings in the U.S. 4th Ed. Available: http://democrats.
e n e r g y c omme r c e . h o u s e . g o v / s i t e s / d e f a u l t / f i l e s / d o c umen t s /
IMS%20Study%20Generic%20Drugs%20$1%20Trill ion%208.2.12.
pdf.Accessed 2012 Sep 5.
10. Trusheim MR, Aitken ML, Berndt ER (2010) Characterizing markets for
biopharmaceutical innovations: Do biologics differ from small molecules?
National Bureau of Economic Research Working Paper No. 16014. Available:
http://www.nber.org/papers/w16014. Accessed 2013 Jan 11.
11. Mullins CD, DeVries AR, Hsu VD, Meng F, Palumbo FB (2005) Variability and
growth in spending for outpatient specialty pharmaceuticals. Health Aff
(Millwood) 24: 1117–1127.
12. Hensley S, Martinez B (15 July 2005) To sell their drugs, companies increasingly
rely on doctors. The Wall Street Journal: A1. Available: http://online.wsj.com/
article/SB112138815452186385.html. Accessed 2013 Jan 10.
13. American Board of Internal Medicine Foundation; American College of
Providers-American Society of Internal Medicine Foundation; European
Federation of Internal Medicine (2002) Medical professionalism in the new
millennium: a physician charter. Ann Intern Med 136: 243–246.
14. Rothman DJ, Chimonas S (2008) New developments in managing physician-
industry relationships. JAMA 300: 1067–1069.
15. Rothman DJ, Chimonas S (2010) Academic medical centers’ conflict of interest
policies. JAMA 304: 2294–2295.
16. Fugh-Berman A, Brown SR, Trippett R, Bell AM, Clark P, et al. (2011) Closing
the door on pharma? A national survey of family medicine residencies regarding
industry interactions. Acad Med 86: 649–654.
17. Chimonas S, Rozario NM, Rothman DJ (2010) Show us the money: lessons in
transparency from state pharmaceutical marketing disclosure laws. Health Serv
Res 45: 98–114.
18. Campbell EG, Rao SR, DesRoches CM, Iezzoni LI, Vogeli C, et al. (2010)
Physician professionalism and changes in physician-industry relationships from
2004 to 2009. Arch Intern Med 170: 1820–1826.
19. O’Reilly K (23 March 2009) Doctors increasingly close doors to drug reps, while
pharma cuts ranks. American Medical News. Available: http://www.
crutchfielddermatology.com/news/images/amednews.pdf. Accessed 2011 Oct
25.
20. United States Food and Drug Administration (2011) Center for Drug Evaluation
and Research drug and biologic approval report. Available: http://www.fda.
g o v / d o w n l o a d s / D r u g s / D e v e l o p m e n t A p p r o v a l P r o c e s s /
HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/
UCM242695.pdf. Accessed 2011 Dec 13.
21. Rader RA (2011) The top 50 biopharma products. Biotechnology Information
Institute. Available: www.contractpharma.com/issues/2011-07/view_features/
the-top-50-biopharma-products. Accessed 2011 Dec 13.
22. Aggarwal A (2010) What’s fueling the biotech engine –2009–2010. Nat
Biotechnol 28: 1165–1171.
23. United States Department of Labor Bureau of Labor Statistics. Available at:
http://www.bls.gov/cpi/#data. Accessed 2011 Dec 21.
24. United States Food and Drug Administration (2011) Summary of NDA
approvals & receipts, 1938 to the present. Available: http://www.fda.gov/
A b o u t F D A / W h a t W e D o / H i s t o r y / P r o d u c t R e g u l a t i o n /
SummaryofNDAApprovalsReceipts1938tothepresent/default.htm. Accessed
2012 Sep 5.
25. Kolata G, Pollack A (6 July 2008) Costly cancer drug offers hope, but also
a dilemma. The New York Times. Available: http://www.nytimes.com/2008/
07/06/health/06avastin.html. Accessed 2011 Dec 13.
26. Groves KEM, Sketris I, Tett SE (2003) Prescription drug samples–Does this
marketing strategy counteract policies for quality use of medicines? J Clin Pharm
Ther 28: 259–271.
27. Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, et al. (2006)
Health industry practices that create conflicts of interest: a policy proposal for
academic medical centers. JAMA 295: 429–433.
28. American Association of Medical Colleges (2008) Protecting patients, preserving
integrity, advancing health: Accelerating the implementation of COI policies in
human subject research. Available: https://www.aamc.org/advocacy/research/
coi/. Accessed 2011 Nov 29.
29. Institute of Medicine (2009) Conflict of interest in medical research, education,
and practice. Available: http://books.nap.edu/openbook.php?record_
id = 12598. Accessed 2009 Dec 15.
30. Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A (2008)
Balancing early market access to new drugs with the need for benefit/risk data:
a mounting dilemma. Nat Rev Drug Discov 7: 818–826.
31. Liang BA, Mackey T (2011) Direct-to-consumer advertising with interactive
internet media. JAMA 305: 824–825.
32. Othman N, Vitry A, Roughead EE (2009) Quality of pharmaceutical
advertisements in medical journals: a systematic review. PLoS One 4: e6350.
doi:10.1371/journal.pone.0006350.
33. Korenstein D, Keyhani S, Mendelson A (2011) Adherence of pharmaceutical
advertisements in medical journals to FDA guidelines and content for safe
prescribing. PLoS One 6: e2336. doi:10.1371/journal.pone.0023336.
34. Gagnon MA, Lexchin J (2008) The cost of pushing pills: a new estimate of
pharmaceutical promotion expenditures in the United States. PLoS Med 5: e1.
doi:10.1371/journal.pmed.0050001.
Promotion of Prescription Drugs
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e55504
